Empa and dapa are approved for heart failure (and lower mortality), a typical disease of aging, while cana is not
There are hints in longitudinal studies that empa and dapa might be neuroprotective while cana is not
Mendelian randomization studies found that SGLT2 inhibition was causally associated with longevity in males (father’s attained age), so the type of SGLT2 inhibitor might not matter that much (although another MR found something similar for SGLT1 and in that case only canagliflozin significantly inhibits SGLT1).
Yes. Thanks for linking those. I used to believe only canagliflozin influenced mTORC1, but after seeing those and some other recent studies, I think empagliflozin is the best choice of SGLT2i.